Related Experiment Video
Updated: Feb 3, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
The association between multiple sclerosis and pain medications
Sarah Burkill1,2, Scott Montgomery2,3,4, Ingrid Kockum5,6
1Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Abstract:
The patients with multiple sclerosis (MS) are at greater risk of pain than people without the disease; however, the occurrence and characteristics of pain among these patients are incompletely described. We aimed to assess characteristics of pain amongst MS patients using MS patients who were recruited to participate in 3 studies in Sweden (n = 3877) and were matched with individuals without MS (n = 4548) by sex, year of birth, and region of residence. The Prescribed Drugs Register identified prescribed pain medication, overall and restricted to those given 4 or more prescriptions in 1 year to assess chronic pain. Anatomical therapeutic chemical codes classified whether pain was neuropathic, musculoskeletal, or migraine. Cox-proportional hazard models were used to estimate associations. Our findings showed the patients with MS were at increased risk of pain treatment, with a hazard ratio (HR) of 2.52 (95% confidence interval 2.38-2.66). The largest magnitude HR was for neuropathic pain (5.73, 5.07-6.47) for which 34.2% (n = 1326) of the MS and 7.15% (n = 325) of the non-MS cohort were prescribed a treatment. The HR for chronic pain treatment was 3.55 (3.27-3.84), indicating an increased effect size relative to any pain treatment. Chronic neuropathic pain showed the largest HR at 7.43 (6.21-8.89). Neuropathic pain was shown to be the primary mechanism leading to increased risk of pain in patients with MS.
Insights
Patients with multiple sclerosis (MS) face a significantly higher risk of pain, particularly chronic neuropathic pain. This study highlights neuropathic pain as the primary driver of increased pain incidence in MS patients.
Area of Science:
- Neurology
- Pain Medicine
- Epidemiology
Background:
- Multiple sclerosis (MS) patients experience a higher prevalence of pain compared to the general population.
- The specific characteristics and prevalence of pain in MS patients remain incompletely understood.
Purpose of the Study:
- To investigate the occurrence and characteristics of pain in a large cohort of multiple sclerosis patients.
- To compare pain treatment patterns between MS patients and matched individuals without MS.
Main Methods:
- Utilized data from three Swedish studies including 3877 MS patients and 4548 matched non-MS individuals.
- Assessed pain treatment using the Prescribed Drugs Register, identifying chronic pain based on medication frequency.
- Classified pain types (neuropathic, musculoskeletal, migraine) using Anatomical Therapeutic Chemical (ATC) codes.
- Employed Cox-proportional hazard models to analyze associations between MS and pain treatment.
Main Results:
- MS patients exhibited a 2.52-fold increased risk of receiving pain treatment (HR 2.52).
- Neuropathic pain showed the highest risk increase (HR 5.73), with 34.2% of MS patients receiving treatment compared to 7.15% of controls.
- Chronic pain treatment risk was elevated (HR 3.55), with chronic neuropathic pain demonstrating the largest hazard ratio (HR 7.43).
Conclusions:
- Neuropathic pain is the predominant factor contributing to the elevated risk of pain in multiple sclerosis patients.
- The findings underscore the significant burden of neuropathic pain in the MS population, necessitating targeted management strategies.
Related Concept Videos
Inhaled Medications
Pain
Association Areas of the Cortex
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Associative Learning
Classical conditioning, also known...
Multiple Allele Traits
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...

